points (odds ratio (OR) 0.49; 95% confidence interval (CI) 0.25 to 0.96). The second AD treatment study (Lloret 2009) explored the effects of vitamin E (800 IU/day) on cognitive progression in relation to oxidative stress levels. Patients whose oxidative stress markers were lowered by vitamin E showed no significant difference in the percentage change in Mini-Mental State Examination (MMSE) score, between baseline and six months, compared to the placebo group. The primary aim of the MCI study (Petersen 2005) was to investigate the effect of vitamin E (2000 IU/day) on the time to progression from MCI to possible or probable AD. A total of 214 of the 769 participants progressed to dementia, with 212 being classified as having possible or probable AD. There was no significant difference in the probability of progression from MCI to AD between the vitamin E group and the placebo group (hazard ratio 1.02; 95% CI 0.74 to 1.41; P = 0.91).
Authors' conclusions
No convincing evidence that vitamin E is of benefit in the treatment of AD or MCI. Future trials assessing vitamin E treatment in AD should not be restricted to alpha-tocopherol.
P L A I N L A N G U A G E S U M M A R Y

Vitamin E should not be used for the treatment of mild cognitive impairment (MCI) and Alzheimer's dementia (AD)
Vitamin E is a dietary compound that has strong antioxidant properties. Vitamin E has been shown to act on some toxic chemicals that may contribute to the damage seen in AD. Many laboratory, animal and epidemiological studies have pointed towards a possible beneficial role for vitamin E in the prevention and treatment of AD. However, to date very limited evidence exists in humans to support the routine use of vitamin E. Further, in recent years evidence has come to light implicating vitamin E with potentially serious side effects and even increased mortality. In this review three studies were identified and these demonstrated no or limited benefit for vitamin E in MCI and AD. Therefore, vitamin E should not be used in the treatment of MCI or AD. More trials are still needed but these should include different forms of vitamin E.
B A C K G R O U N D
Description of the condition
Alzheimer's dementia (AD) is a progressive neurodegenerative disease resulting in deficits in multiple cognitive domains, including memory, language and executive functioning, as well as a variety of emotional and behavioural symptoms. This subsequently leads to progressive functional impairment. AD causes huge emotional and financial burden to patients, carers, and health and social care systems. Current treatments for AD have limited efficacy and cannot prevent progression of the condition. It is projected that one in 85 people will suffer from the disease by 2050, equating to a worldwide prevalence of 106.2 million cases (Brookmeyer 2007). Mild cognitive impairment (MCI) is a condition that results in cognitive deficits but does not meet the diagnostic criteria for dementia. There has been much controversy over the status of MCI; whether it is a discrete disorder, a continuation of normal ageing or precursor to dementia. Regardless, what is known is that those with MCI are at a greater risk of developing dementia (Ganguli 2011). It is currently estimated that between 10% and 20% of people over the age of 65 years suffer from MCI (Petersen 2011), which is expected to increase along with the increasing prevalence rates of AD. 
Description of the intervention
O B J E C T I V E S
To assess the efficacy of vitamin E in the treatment of AD and MCI.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All unconfounded, randomised, double-blind trials identified in the search in which vitamin E was compared with placebo in the treatment of patients with MCI or AD, or both, were studied. Trials in which allocations to treatment were not randomised, or in which treatment allocations were not concealed were excluded.
Types of participants
Participants for treatment of AD in included trials were diagnosed with probable AD according to internationally accepted diagnostic criteria including NINCDS-ADRDA ( 
Types of interventions
Any dosage of vitamin E or any of its constituent tocopherols or tocotrienols. Co-administration of another drug with vitamin E was permitted if the same drug was also taken by the placebo group.
Types of outcome measures
All outcome measures had to derive from validated, published scales.
Primary outcomes
• Development of, or time to development of, possible AD from MCI.
• Cognitive function.
• Adverse events.
• Death.
Secondary outcomes
• Global measure of severity and deterioration.
• Behavioural disturbance.
• Mood.
• Activities of daily living.
• Carer burden.
• Quality of life.
• Permanent physical disability.
• Institutionalisation. To view a list of all sources searched for ALOIS see About ALOIS on the ALOIS website. Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the 'methods used in reviews' section within the editorial information about the Dementia and Cognitive Improvement Group. Additional searches were performed in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up-to-date and as comprehensive as possible. The search strategies used can be seen in Appendix 1.
Search methods for identification of studies
Data collection and analysis
Selection of studies
Three review authors (NF, MI, and NT) independently examined the title and abstract of the papers identified by the search and selected them for their relevance to the review. The selected citations were retrieved. All disagreements concerning inclusion were resolved by discussion. Inclusion criteria were clearly defined.
Data extraction and management
Data were extracted by one review author (NT for Sano study, MI for Petersen study, and NF for Lloret study). An attempt was made to collect the following data:
• report -author, year and source of publication;
• study -study setting;
• patients -demographics, diagnostic criteria for AD or MCI, exclusion criteria, other concomitant medical conditions or medications that may affect cognition;
• research design and features -sampling mechanism, treatment assignment mechanism, blinding, drop-out rates, length of follow-up, pertinent design features (e.g. cross-over design);
• intervention -type, duration, dose, timing, mode of delivery;
• outcome measures;
• results -number of patients randomised, outcome data.
For each outcome measure, data were sought on every patient randomised. Intention-to-treat data were preferred. If these were not available, data were extracted on patients who completed treatment. Data were not extracted for any non-randomised titration periods or any open-label follow-on phases.
For continuous data the means, standard deviation (SD) and number of participants in each treatment group at each time point were extracted. Change from baseline data were extracted if end-point data were unavailable. For binary data, the data extracted was the number of patients with each outcome in each treatment group at each time point. For ordinal data, there were two possible approaches. If ordinal scale data appeared to be approximately normally distributed or if the analysis that the investigators performed suggested that parametric tests were appropriate, then the outcome measures were treated as continuous data. The second approach, which may not exclude the first, was to concatenate into two categories that best represent the contrasting states of interest, and to treat the variable as binary.
For time-to-event data, a hazard ratio (HR) was sought.
Assessment of risk of bias in included studies
Risk of bias was assessed by NF and MI for each included study was assessed based upon the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The following criteria were assessed:
• sequence generation;
• allocation concealment;
• blinding (participants);
• blinding (investigators); • incomplete outcome reporting;
• selective outcome reporting.
For each study, a risk of bias rating ('Low risk', 'Unclear risk' or 'High risk') was given for each of the above criteria. Empirical re-search has shown that lack of adequate allocation concealment may be associated with bias. Trials with unclear concealment measures have been shown to yield more pronounced estimates of treatment effects than trials that have taken adequate measures to conceal allocation schedules, but less pronounced than inadequately concealed trials (Chalmers 1983; Schulz 1995). Thus trials were included if they conform to 'Low risk' or 'Unclear risk' allocation risk categories, while those falling into 'High risk' category were excluded.
Measures of treatment effect
For studies with continuous outcome measures, mean differences or standardised mean differences were calculated. For binary outcome measures odds ratio (OR) were calculated. For time-to-event outcome measures, HRs were calculated.
Unit of analysis issues
The participant was the unit of analysis. No cross-over studies were identified.
Dealing with missing data
An intention-to-treat analysis was carried out where possible. In cases where only completers' data were available the impact of the missing data on the findings was explored, where possible. A sensitivity analysis was carried out in one study (Petersen 2005) to investigate the impact of a high drop-out rate.
Assessment of heterogeneity
Owing to the significant clinical and methodological heterogeneity between studies, results were not synthesised and no statistical tests for heterogeneity were performed.
Assessment of reporting biases
There was an insufficient number of studies identified to make any quantitative assessment.
Data synthesis
It was not possible to synthesise and compare data across studies as there were no comparable outcome measures.
Subgroup analysis and investigation of heterogeneity
Although not specified in the protocol, data were extracted and reported for a subgroup analysis carried out in one included study. The subgroups were participants who did or did not show a decline in markers of oxidative stress in response to vitamin E treatment. This subgroup was considered important to include as a reduction of oxidative stress is thought to be the mechanism by which vitamin E may affect cognition. 
R E S U L T S Description of studies
Treatment of Alzheimer's dementia
The primary purpose of the first treatment study by Sano 1996 was to determine whether selegiline (a monoamine oxidase inhibitor), alpha-tocopherol (vitamin E) or a combination of the two agents would slow the clinical deterioration associated with AD. Both selegiline and vitamin E were tested using a factorial 2x2 design, with four groups: placebo, selegiline (10 mg total daily dose divided into two doses), vitamin E (2000 IU total daily dose divided into two doses) and selegiline (10 mg total daily dose divided into two doses) plus vitamin E (2000 IU total daily dose divided into two doses). A total of 341 subjects with a diagnosis of probable AD and with moderate severity (Clinical Dementia Rating (CDR) 2) (Berg 1988), were recruited from 23 centres in the US. For further details about the study refer to the Characteristics of included studies. Assessments were conducted one month after enrolment and at three-monthly intervals for two years. The primary outcome was the survival time to any one of four end points; death, institutionalisation, change in severity of dementia to a CDR of three or loss of two basic activities of daily living. After the primary end point was reached, every effort was made to continue further assessment of the secondary outcomes if possible. ). The secondary outcomes were assessed at one month, and then every three months until two years. The purpose of the second treatment study (Lloret 2009) was to explore the effects of vitamin E on AD progression and markers of oxidative stress. Vitamin E (800 IU) or placebo was given daily for six months. There were 57 participants diagnosed with probable AD. All AD participants were taking a cholinesterase inhibitor and were not on any other antioxidant medication. Assessments were conducted on the first day of enrolment and six months after. Oxidative stress was assessed in two ways. The first method used blood concentrations of the oxidised glutathione molecule, GSSG, with greater levels indicating greater oxidative stress. GSSG was also assessed as a ratio with the antioxidant molecule glutathione. Further the blood marker MDA was measured as a marker of lipid peroxidation, which is a strong indicator of oxidative damage. AD progression was measured by the Clock drawing test (Sunderland 1989), the BDS (Blessed 1968) and MMSE (Folstein 1975) . For further details about the study refer to the Characteristics of included studies. The primary analysis was to compare performance on the cognitive tasks in relation to the effects of vitamin E on oxidative stress. Vitamin E-treated participants were divided into responders and non-responders according to whether vitamin E was effective or not in reducing markers of oxidative stress. The responder, non-responder and placebo group means were compared using a Kruskal-Wallis test. Comparison between groups was also undertaken following removal of participants with cerebrovascular disease. To determine the effect of modifying oxidative stress on cognitive performance -the relationship between MMSE change and GSSG change in patients treated with vitamin E was assessed using Spearman's coefficient of correlation. The effects of vitamin E on oxidative stress markers were investigated using a Mann-Whitney test to compare GSSG and MDA values at the beginning of the study and the end of the study in both the placebo and active treatment conditions.
Prevention of progression of cognitive impairment
The the Characteristics of included studies. The primary analysis was conducted according to an intentionto-treat principle to determine whether there was a significant reduction in time to progression to AD among subjects treated with either vitamin E or donepezil as compared with those given placebo. The Cox proportional-hazards model was used, and the baseline variables were included in the analysis as covariates. Two primary analyses were conducted, one comparing the vitamin E and placebo groups, which was the main interest of this review, and one comparing the donepezil and placebo groups. The Hochberg method (Hochberg 1988) was used to adjust the two P values for multiple comparisons. The Schoenfeld residuals test was used to test for non-proportional hazards (Schoenfeld 1982). A z test was used to compare estimated survival rates at various points on the Kaplan-Meier curves (at 6, 12, 18, 24 and 36 months). The Hochberg method was used to adjust the six P values for multiple comparisons. Subgroup analysis for apolipoprotein E4 (ApoE4) carriers was conducted using HRs derived from the Cox analysis. The secondary outcomes were examined with the use of covariance for the change in the scores without correction for multiple comparisons, and missing values were input with the use of a projection method appropriate for assessing responses among subjects with neurodegenerative diseases.
Risk of bias in included studies
Random sequence generation (selection bias)
We judged that all three studies had a low risk of bias.
Allocation (selection bias)
Concealment of participant allocation according to the randomisation sequence was unclear in the three studies as they did not clearly refer to how the ensured allocation concealment.
Blinding of participants and personnel (performance bias)
All studies had an unclear risk of bias as they did not report what steps were taken to ensure that participants and personnel remained blinded to treatment allocation.
Blinding of outcome assessment (detection bias)
Only the Petersen 2005 study reported evidence that assessors were blinded to the outcomes. There were unclear risks of bias in the Lloret 2009 and Sano 1996 studies as they did not refer to blinding during outcome assessment.
Incomplete outcome data (attrition bias)
Only Petersen 2005 investigated the impact of the drop-out. Sano 1996 reported the attrition rate but did not give reasons, and hence is judged as an unclear risk of bias. Lloret 2009 reported a very high attrition rates and did not give reasons, as such it was judged as a high risk of bias.
Selective reporting (reporting bias)
All studies reported outcomes stated in their protocol.
Other potential sources of bias
No other sources of bias were found. See Figure 1 for the summary of the risk of bias. 
Effects of interventions
Treatment of Alzheimer's dementia
The treatment study (Sano 1996) had four treatment groups, but data from only two of the groups were evaluated. These were the groups receiving placebo only and vitamin E only. The selegiline and selegiline plus vitamin E groups were excluded because there was no placebo control for the vitamin E. Sano 1996 reported the number in each outcome group who reached the primary end point within two years for the completers only. The analysis of data of those reaching end point showed benefit associated with vitamin E (58% (45/77) of patients in the vitamin E group reached end point compared with 74% (58/78) in the placebo group; OR 0.49; 95% confidence interval (CI) 0.25 to 0.96). Because the trial was limited in time, this analysis, comparing a count of events without taking into account the timing of events, should still be valid but is less precise than the survival analysis reported by Sano 1996. Using Kaplan-Meier estimation and log-rank testing in their primary analysis, Sano 1996 found no significant difference in survival time to one of the four end points between the vitamin E and placebo groups (RR 0.70; P = 0.08). However, the study groups differed in baseline MMSE scores and these were correlated with clinical course. The vitamin E group began with a mean MMSE of 11.3 (SD 5.7) and the placebo group with a mean of 13.3 (SD 4.9). When the analysis was repeated using the Cox proportional hazards model and controlling for baseline MMSE a significant difference favouring vitamin E emerged (RR 0.47; P = 0.001). No statistical analysis was performed on secondary outcome measures data as only mean change scores to the time point where a patient was last assessed were reported and patients had been assessed over varying and unidentified time spans. Six patients from the placebo group and eight from the vitamin E group were lost to follow-up before reaching an end point, but there is no information on the time points at which these patients were lost. A total of 49 categories of adverse events were defined but the only results initially reported were for three categories, in which significant differences between one or more of the treatment groups and the placebo group were found. However, once the authors made adjustments for multiple comparisons no significant differences between groups were found. Lloret 2009 divided participants treated with vitamin E into two groups depending on changes in oxidative stress markers with treatment. Those who showed a decrease in GSSG values of more than 10 nmol per mL of blood after six months of vitamin E treatment were termed 'responders' and those who did not were termed 'non-responders'. These groups had not been defined in advance of data collection. They reported 'completers' results only (33/ 57 randomised patients). The percentage change in performance from baseline to six months on the BDS, Clock drawing test and MMSE were then compared across responders (N = 9), non-responders (N = 10) and placebo-treated groups (N = 14). There was no significant difference reported between groups on the Clock drawing test or BDS. The MMSE score increased in the responder group but decreased in the placebo group and more so in the non-responders. A significant difference was reported between the two vitamin E-treated groups (P < 0.05). The responders did not differ significantly from the placebo-treated group. The decline in MMSE in the non-responders was significantly greater than in the placebo group (P < 0.05).
Lloret 2009 reported a negative correlation between change in MMSE score and change in blood levels of GSSG from baseline to six months; that is, there was a greater decline in cognitive performance in AD patients whose blood GSSG levels stayed higher (reflecting higher oxidative stress).
No data were presented with regards to the effects of vitamin E on cognitive measures in the treated group as a whole compared to the placebo group. Subgroups could not be combined as data were reported as statistical changes only and the data set was not made available.
MCI and the prevention of progression of cognitive impairment
The prevention study (Petersen 2005) had three treatment groups of people with MCI, but only data from the vitamin E and placebo groups were evaluated. The donepezil group was excluded. The primary outcome was the time to the development of possible or probable AD. Petersen 2005 reported that over the three years of the trial, there was no significant difference in the probability of progression from MCI to AD on the basis of Cox analysis between the vitamin E group and placebo group (HR 1.02; 95% CI 0.74 to 1.41; P = 0.91). The 36-month analysis was followed by a pre-specified assessment of the treatment effects at each sixmonth evaluation point. This analysis showed that there was no significant difference between vitamin E and placebo groups on the primary outcome at any time point measured during the trial. A total of 38 subjects (out of 259) in the placebo group and 33 subjects (out of 257) in the vitamin E group had progression to AD in the first 12 months. By 36 months, the numbers of subjects with progression to AD did not differ, with 73 in the placebo group and 76 in the vitamin E group. Although subjects were assessed at 6, 12, 18, 24, 30 and 36 months, numbers were only reported for 12 and 36 months; for the remainder only changes from baseline were reported. A total of 138 subjects discontinued treatment in the placebo group (N = 72) and the vitamin E group (N = 66). The leading reasons for dropout were death, adverse events and withdrawal of consent. However, there was no information on the distribution of reasons for dropout across groups. The authors carried out sensitivity analysis and z-testing to assess the effect of missing data as a result of dropouts and concluded that the results of these analyses were non-significant. Changes in cognitive function scores from baseline to each of the six-monthly time points were reported in both vitamin E and placebo groups. No significant increases in any cognitive domain scores were reported compared to baseline in the placebo group. There were a few differences compared to baseline in the vitamin E group and those that were seen (in the executive, language and overall cognitive scores) were confined to the first 18 months of the study. Specifically, executive function was significantly greater at six months compared to baseline in the vitamin E group (P < 0.05). Language scores were significantly greater compared to baseline in the vitamin E group at six months (P < 0.05), 12 months (P < 0.05) and 18 months (P < 0.05). Overall cognitive scores in the vitamin E group were significantly greater at six months compared to baseline (P < 0.01). No between-group comparisons were reported for the secondary outcomes.
D I S C U S S I O N
Three studies met the inclusion criteria and were selected for this review. To our knowledge there are currently no relevant ongoing trials. Two studies (Lloret 2009; Sano 1996) assessed the efficacy of vitamin E in AD patients while one study (Petersen 2005) assessed vitamin E in MCI patients. A significant limitation of this review is that synthesis of data from the AD studies was not possible owing to different outcome measures. The primary outcome measures from the Lloret 2009 study were performance-based cognitive tasks. Conversely the primary outcome measure in the Sano 1996 study was reaching a series of clinical end points. It would not have been appropriate to pool data from the MCI study with those from the AD studies as the MCI study evaluated a distinct diagnostic entity.
There was no strong evidence that vitamin E when compared to placebo was efficacious in improving outcomes of AD. In the Sano 1996 study there was no significant difference between vitamin E and placebo group when using unadjusted data, although adjusted data presented showed a significant delay to the primary end point.
Lloret 2009 implemented very different outcome measures compared to Sano 1996, measuring changes in cognitive performance as opposed to an end point index. Performance change was compared between responders and non-responders (as determined by the degree of change in markers of oxidative stress, defined post hoc) and a placebo group. The Lloret 2009 study has opened a new research avenue for studying the response to vitamin E among different patient subgroups. We agree with Brewer 2010 and Lloret 2009 that future research should also include concomitant measurement of antioxidants and oxidative stress markers. However, the Lloret 2009 study itself needs to be considered exploratory in nature. The mechanisms that may explain why only a proportion of patients respond 'oxidatively' to the antioxidant vitamin E remains unknown. Another significant limitation is the small number of participants, which made the subsequent subgroup analysis less informative. A further limitation is the high drop-out rate reported. Notwithstanding the limitations of this study, in those patients where vitamin E did not reduce oxidative stress there was a paradoxical accelerated decline in cognitive abilities compared to placebo. Hence, additional caution is needed in the design of future clinical trials utilising vitamin E treatment.
Petersen 2005 found no difference in the probability of progression from MCI to AD between the vitamin E group and placebo group during the three years of the study. Therefore the investigators carried out a pre-specified assessment of the treatment effect at each six-month evaluation point. The analysis confirmed that there was no significant difference between the vitamin E and placebo groups at any time during the trial. Vitamin E was also shown to have very limited efficacy of improving cognitive outcomes in a few cognitive domains. All cognitive improvements dissipated after 18 months of treatment. Conclusions are necessarily limited because no between-group analysis was conducted.
Old age is associated with vitamin E deficiency (Dror 2011). However, there is a difference between addressing deficiency with adequate daily recommended levels and the use of high or very high doses of vitamin E. The latter is much more likely to produce significant side effects. High doses of alpha-tocopherol also have potential to induce enzymes involved in drug metabolism with an associated risk of serious interactions with some concomitant medication (Brigelius-Flohé 2007).
Vitamin E assessed in epidemiological studies in relation to cognition has consisted of the various naturally occurring forms (Engelhart 2002; Morris 2002; Morris 2005). These studies have generally reported a positive association between intake of vitamin E and cognition. Morris 2005 suggested that the combined intake of tocopherols is likely to be more important than alphatocopherol alone. This is further supported by Mangialasche 2010 who studied the relationship between cognitive impairment and the eight individual forms of vitamin E and concluded that any potential neuroprotective effect for vitamin E may result from interaction of various forms. In addition to the forms of vitamin E used, the potential biological benefits of vitamin E did not translate to an effective treatment of AD and MCI possibly owing to the relatively short intervention period.
Implications for practice
This review found no evidence for efficacy of vitamin E in the treatment of AD. Taken together with other evidence that vitamin E, especially in the large doses used in the included studies, may be associated with potentially significant side effects and even an increased rate of all-cause mortality (Miller 2005), we conclude that vitamin E should not be used in the treatment of AD. We consider it important to educate patients, carers and professionals alike about the lack of confirmed efficacy and the potential hazards of using vitamin E in AD. It is important to note that the efficacy conclusions are based only on the alpha-tocopherol formulation of vitamin E, and hence no comment can be made on the efficacy of other preparations.
Implications for research
Vitamin E is a powerful antioxidant and plays an important role in protecting cells against the harmful effects of free radicals. There is sufficient evidence from laboratory and animal studies to justify human investigation of this medicinal product for AD patients. However, there continues to be a paucity of RCTs investigating the efficacy of vitamin E in AD. The study of Lloret, which met the inclusion criteria for this study, is of interest as it showed a harmful effect on the cognition in those patients whose oxidative stress markers did not respond to vitamin E intake (Lloret 2009). However, the high number of drop-outs in this study limits the conclusions that can be made. Findings are in need of replication from sufficiently powered clinical trials incorporating the assessment of oxidative stress markers in order to understand further the oxidant-antioxidant balance in relation to vitamin E effects on AD. In addition, the exclusive use of the alpha-tocopherol form of vitamin E in clinical trials has been questioned. Therefore, future studies must not restrict treatment to alpha-tocopherol, and should investigate other tocopherol and tocotrienol forms. Future updates of this review will specify sub-groups by vitamin E formulation and oxidative stress response.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
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